The stock market is down Monday, with the Dow Jones Industrial Average down 0.08%, the Nasdaq down 0.27% and the S&P 500 down 0.21%. Today’s winners were both getting bought out. One of today’s losers is a pharmaceutical company which reported mixed results on a drug trial, while another loser had its shares downgraded by a big bank.
These are Monday’s market winners and losers.
Biggest Winners
Shares of IRIS International Inc. (NASDAQ: IRIS) are up 44.93% to $19.45 on trading volume of 1.4 million shares. Danaher Corp. (NYSE: DHR) said it would buy the medical firm for $355 million, or $19.50 a share. Before Monday, the 52-week high was $13.92.
Shares of Complete Genomics Inc. (NASDAQ: GNOM) are up 14.61% to $3.06 on trading volume of 3.9 million shares. Chinese firm BGI-Shenzhen is buying the company for $117.6 million, or $3.15 a share. The 52-week high is $7.73.
Biggest Losers
Shares of Threshold Pharmaceuticals Inc. (NASDAQ: THLD) are down 26.84% to $6.38 on trading volume of 6 million shares. The company reported mixed results following a clinical trial for its drug which treats pancreatic cancer. The 52-week low is $1.18.
Shares of Groupon Inc. (NASDAQ: GRPN) are down 6.07% to $4.95 on trading volume of 3.3 million shares. Investment bank Evercore Partners has added the daily deals company to its “Conviction Sell List,” according to flyonthewall.com. The 52-week low is $4.00.
Samuel Weigley
Follow him on Twitter: SWeigley
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
